ABSTRACT
Herein we describe the discovery of ACP-105 (1), a novel and potent nonsteroidal selective androgen receptor modulator (SARM) with partial agonist activity relative to the natural androgen testosterone. Compound 1 was developed from a series of compounds found in a HTS screen using the receptor selection and amplification technology (R-SAT). In vivo, 1 improved anabolic parameters in a 2-week chronic study in castrated male rats. In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer.
Subject(s)
Androgen Receptor Antagonists , Androgens , Azabicyclo Compounds/chemistry , Azabicyclo Compounds/pharmacology , Administration, Oral , Animals , Azabicyclo Compounds/metabolism , Azabicyclo Compounds/pharmacokinetics , Dogs , Drug Design , Humans , Ligands , Male , Mice , Microsomes, Liver/metabolism , Mutation , NIH 3T3 Cells , Orchiectomy , Prostatic Neoplasms/genetics , Rats , Receptors, Androgen/genetics , Receptors, Androgen/metabolism , Structure-Activity Relationship , Substrate Specificity , Testosterone Propionate/pharmacologyABSTRACT
A novel class of CB1 inverse agonists was discovered. To efficiently establish structure-activity relationships (SARs), new synthetic methodologies amenable for parallel synthesis were developed. The compounds were evaluated in a mammalian cell-based functional assay and in radioligand binding assays expressing recombinant human cannabinoid receptors (CB1 and CB2). In general, all of the compounds exhibited high binding selectivity at CB1 vs CB2 and the general SAR revealed a lead compound 11-(4-chlorophenyl)dibenzo[b,f][1,4]thiazepine-8-carboxylic acid butylamide (12e) which showed excellent in vivo activity in pharmacodynamic models related to CB1 receptor activity. The low solubility that hampered the development of 12e was solved leading to a potential preclinical candidate 11-(3-chloro-4-fluorophenyl)dibenzo[b,f][1,4]thiazepine-8-carboxylic acid butylamide (12h).